Patient flowchart of recruitment and treatment failure and success with glyburide vs. metformin. Treatment failure was defined as either poor glycemic control, in which case an additional oral hypoglycemic drug was added, or adverse effects leading to drug discontinuation, in which case the treatment was switched to the second-line treatment. If addition/switching to the second-line treatment resulted in poor glycemic control or adverse effects leading to drug discontinuation, the treatment was switched to insulin (third-line therapy). No statistical difference was found between the rate of poor glycemic control (P = 0.6) and adverse effects (P = 0.11) of glyburide vs. metformin after the first-line therapy. No statistical difference was found for second-line therapy between the groups (P = 0.6). The need for third-line therapy with insulin was lower in the metformin group than in the glyburide group (P = 0.03).
Glycemic control under treatment according to daily glucose charts of glyburide vs. metformin throughout the study period. A: Box plot representing the mean daily, preprandial, and postprandial glucose values throughout the study period. B–D: LOESS curves (smoothing parameter 0.8) representing the mean daily, preprandial, and postprandial glucose values at each week of gestation. The difference between the postprandial glucose values (D) during 26–36 weeks gestation was not statistically significant (Wilcoxon two-sample test P = 0.18).